The relation between bisphosphonate use and non-union of fractures of the humerus in older adults
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
While nitrogen-containing bisphosphonates have been shown to reduce fracture risk in postmenopausal women and men, their safety in the period after a fracture is unclear. In fully adjusted multivariable regression models, bisphosphonate use in the post-fracture period was associated with an increased probability of non-union [odds ratio (OR) 2.37, 95% confidence interval (CI) 1.13–4.96]. Clinicians might consider waiting for several months before introduction of a bisphosphonate after a fracture.
While nitrogen-containing bisphosphonates have been shown to reduce fracture risk in postmenopausal women and men, their safety in the period after a fracture is unclear. We examined the risk of non-union associated with post-fracture bisphosphonate use among a group of older adults who had experienced a humerus fracture.
We conducted a nested case–control study among subjects who had experienced a humerus fracture. From this cohort, cases of non-union were defined as those with an orthopedic procedure related to non-union 91–365 days after the initial humerus fracture. Bisphosphonate exposure was assessed during the 365 days prior to the non-union among cases or the matched date for controls. Multivariable logistic regression models were examined to calculate the OR and 95% CI for the association of post-fracture bisphosphonate use with non-union.
From the cohort of 19,731 patients with humerus fractures, 81 (0.4%) experienced a non-union. Among the 81 cases, 13 (16.0%) were exposed to bisphosphonates post-fracture, while 69 of the 810 controls (8.5%) were exposed in the post-fracture interval. In fully adjusted multivariable regression models, bisphosphonate use in the post-fracture period was associated with an increased odds of non-union (OR 2.37, 95% CI 1.13–4.96). Albeit limited by small sample sizes, the increased risk associated with bisphosphonate use persisted in the subgroup of patients without a history of osteoporosis or prior fractures (OR 1.91, 95% CI 0.75–4.83).
In this study of older adults, non-union after a humerus fracture was rare. Bisphosphonate use after the fracture was associated with an approximate doubling of the risk of non-union.
- Cranney A, Guyatt G, Griffith L et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23(4):570–578 CrossRef
- Little DG, Ramachandran M, Schindeler A (2007) The anabolic and catabolic responses in bone repair. J Bone Jt Surg, Br Vol 89(4):425–433 CrossRef
- Fleisch H (2001) Can bisphosphonates be given to patients with fractures? J Bone Miner Res 16(3):437–440 [comment] CrossRef
- Cao Y, Mori S, Mashiba T et al (2002) Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17(12):2237–2246 CrossRef
- Peter CP, Cook WO, Nunamaker DM, Provost MT, Seedor JG, Rodan GA (1996) Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 14(1):74–79 CrossRef
- Boyce RW, Paddock CL, Gleason JR, Sletsema WK, Eriksen EF (1995) The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res 10(2):211–221 CrossRef
- Li J, Mori S, Kaji Y, Kawanishi J, Akiyama T, Norimatsu H (2000) Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. J Bone Miner Res 15(10):2042–2051 CrossRef
- Amanat N, McDonald M, Godfrey C, Bilston L, Little D (2007) Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 22(6):867–876 CrossRef
- Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809 [see comment] CrossRef
- Nguyen TV, Center JR, Sambrook PN, Eisman JA (2001) Risk factors for proximal humerus, forearm, and wrist fractures in elderly men and women: the Dubbo Osteoporosis Epidemiology Study. Am J Epidemiol 153(6):587–595 CrossRef
- Lauritzen JB, Schwarz P, McNair P, Lund B, Transbol I (1993) Radial and humeral fractures as predictors of subsequent hip, radial or humeral fractures in women, and their seasonal variation. Osteoporos Int 3(3):133–137 CrossRef
- Ray WA, Griffin MR, Fought RL, Adams ML (1992) Identification of fractures from computerized Medicare files. J Clin Epidemiol 45(7):703–714 CrossRef
- Healy WL, Jupiter JB, Kristiansen TK, White RR (1990) Nonunion of the proximal humerus. A review of 25 cases. J Orthop Trauma 4(4):424–431
- Foster RJ, Dixon GL Jr, Bach AW, Appleyard RW, Green TM (1985) Internal fixation of fractures and non-unions of the humeral shaft. Indications and results in a multi-center study. J Bone Jt Surg, Am Vol 67(6):857–864
- Wheeless CR (2007) Wheeless’ textbook of orthopaedics. Data Trace, Towson
- Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323–337 CrossRef
- Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ (2001) Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154(9):854–864 CrossRef
- Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619 CrossRef
- Rothman KJ, Greenland S (1998) Modern epidemiology. Lippincott Williams and Wilkins, Philadelphia
- Horwitz RI, Feinstein AR (1980) The problem of “protopathic bias” in case-control studies. Am J Med 68(2):255–258 CrossRef
- Bhattacharyya T, Levin R, Vrahas MS, Solomon DH (2005) Nonsteroidal antiinflammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum 53(3):364–367 CrossRef
- McDonald MM, Dulai S, Godfrey C, Amanat N, Sztynda T, Little DG (2008) Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone 43(4):653–662
- The relation between bisphosphonate use and non-union of fractures of the humerus in older adults
Volume 20, Issue 6 , pp 895-901
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Division of Pharmacoepidemiology, Harvard Medical School, Boston, MA, USA
- 2. Division of Rheumatology, Immunology, and Allergy, Harvard Medical School, Boston, MA, USA
- 3. Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- 7. Division of Rheumatology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA, 02115, USA
- 4. Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, USA
- 5. Department of Medicine and Division of Gerontology, University of Maryland School of Medicine, Baltimore, MD, USA
- 6. Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD, USA